PXMD (PaxMedica) Other Current Liabilities: $0.00 Mil (As of Sep. 2024)


What is PaxMedica Other Current Liabilities?

PaxMedica PXMD Other Current Liabilities is $0.00 Mil as of Sep. 2024.

PaxMedica's other current liabilities for the quarter that ended in Sep. 2024 was $0.00 Mil.

PaxMedica's annual other current liabilities declined from Dec. 2021 ($9.34 Mil) to Dec. 2022 ($0.66 Mil) but then increased from Dec. 2022 ($0.66 Mil) to Dec. 2023 ($0.79 Mil).

PaxMedica Other Current Liabilities Related Terms

PaxMedica Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for PaxMedica's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PaxMedica Other Current Liabilities Chart

PaxMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Liabilities
Get a 7-Day Free Trial 0.00 4.06 9.34 0.66 0.79

PaxMedica Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.79 0.00 0.00 0.00

PaxMedica Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.00 Mil mean?
PaxMedica (PXMD) has a Other Current Liabilities of $0.00 Mil as of Sep. 2024. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on PaxMedica.
Is PaxMedica's Other Current Liabilities too high?
PaxMedica's current Other Current Liabilities is $0.00 Mil.
How does PaxMedica's Other Current Liabilities compare to BTAX and NBIO?
PaxMedica's Other Current Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on PaxMedica. PaxMedica's current Other Current Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PaxMedica stock overvalued right now?
PaxMedica (PXMD) has a current Other Current Liabilities of $0.00 Mil. The current Other Current Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For PaxMedica (PXMD), the current Other Current Liabilities is $0.00 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PaxMedica Business Description

Address 303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.